Mobio Technologies, Inc.

Mobio Technologies, Inc.

0.08
CAD
-0.02
(-25.00%)
-0.10EPS
8.38MMarket Cap
Mobio Technologies, Inc.
NEO:MBO
(Cboe Canada)

Recent

price

0.08

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
CAD
9.67
2.86
1.25
0.32
0.05
0.61
0.21
0.19
0.02
- -
- -
- -
- -
- -
- -
- -
0.13
Revenue per Share
-5.04
-1.87
-0.83
-1.15
-2.56
-6.68
-1.75
-1.58
-0.14
-0.06
-0.02
-0.01
-0.04
-0.01
-0.01
-0.01
-0.1
Basic EPS, GAAP
-2.6
-0.86
-0.46
- -
-2.43
-4.83
-0.32
-0.33
-0.09
-0.04
-0.03
-0.01
-0.01
- -
-0.01
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-4.51
-0.86
-1.69
-2.78
2.75
3.06
1.46
0.1
0.02
- -
0.03
0.03
-0.01
-0.02
-0.02
-0.03
-0.01
Book Value per Share
-4.51
-0.86
-1.69
-2.78
0.92
0.38
0.22
-0.05
0.02
- -
0.03
0.03
-0.01
-0.02
-0.02
-0.03
-0.03
Tangible Book Value per Share
- -
- -
- -
- -
1
2
3
3
14
16
29
38
38
38
42
43
106
Basic Weighted Avg Shares
1
- -
- -
- -
- -
1
1
1
- -
- -
- -
- -
- -
- -
- -
- -
14
Sales/Revenue/Turnover
-52.11
-57.57
-66.44
-441.41
-5,240.45
-969.94
-624.37
-612.76
-666.18
-1,084.38
-1,822.43
-9,499.75
-1,872.32
-2,484.06
-3,635.94
-11,596.5
-0.45
Operating Margin (%)
- -
- -
- -
- -
- -
2
2
2
1
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
-2
-10
-5
-5
-2
-1
-1
- -
-1
- -
- -
-1
-11
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-52.09
-65.35
-66.44
-360.36
-5,579.24
-1,100.88
-819.95
-846.31
-660.62
-1,336.79
-1,402.89
-5,176.44
-10,583.85
-2,698.12
-4,655.02
-13,632.44
-76.45
Profit Margin (%)
- -
- -
- -
- -
- -
1
1
- -
- -
-1
- -
- -
- -
-1
-1
-1
2
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
5
LT Debt
- -
- -
- -
- -
3
8
4
1
- -
- -
1
2
- -
-1
-1
-1
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
-195.4
-75.69
-211.92
-451.89
- -
- -
-22.74
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

CAD

•

in mil. unless spec.
Jan'25
Jun'25
Jun'25
ST Debt
1
- -
1
LT Borrowings
- -
3
5
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
43
109
112
Market Capitalization
- -
10
8

Working Capital

CAD

•

in mil. unless spec.
Jan'25
Jun'25
Jun'25
Total Current Assets
- -
3
5
Cash, Cash Equivalents & STI
- -
2
4
Accounts Receivable, Net
- -
1
1
Inventories
- -
- -
- -
Total Current Liabilities
2
2
3
Payables & Accruals
- -
2
2
ST Debt
1
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

CAD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3,643.99%
24.13%
71.66%
Free Cash Flow
-5.99%
-6.06%
59.02%
Net Income, GAAP
28.09%
95.75%
94.85%
Sales/Revenue/Turnover
-20.02%
0.51%
-33.47%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
3
5
4
3
- -

Quarterly Earnings Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.01
2025
-0.01
- -
-0.11
- -
- -

Quarterly Dividends Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Business
Mobio Technologies Inc. (TSXV: MBO) develops and commercializes innovative diagnostic technologies for the detection of infectious diseases and critical health conditions. The company offers rapid diagnostic tests including the Illumigen-Dx instrument and associated test cartridges for point-of-care applications; molecular diagnostic assays targeting respiratory pathogens, gastrointestinal infections, and sexually transmitted diseases; and digital health platforms for result reporting and telemedicine integration. Founded in 2021 and headquartered in Richmond, British Columbia, Canada, Mobio operates primarily in North America with expansion into European and Asian markets serving clinical laboratories, hospitals, and primary care providers. In late 2024, the company secured a C$10 million strategic funding round led by existing investors to accelerate commercialization of its next-generation PCR-based diagnostics; formed a key partnership with a major Canadian health network for pilot deployments; and launched the Mobio One platform, a cloud-connected system enhancing test throughput by 40%. These developments position Mobio as a leader in decentralized diagnostics amid growing demand for at-home and rapid testing solutions.